{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:13:26Z","timestamp":1785338006111,"version":"3.55.0"},"reference-count":161,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract.<\/jats:title>\n            <jats:p>Desirable outcomes including rejection- and infection-free kidney transplantation are not guaranteed despite current strategies for immunosuppression and using prophylactic antimicrobial medications. Graft survival depends on factors beyond human leukocyte antigen matching such as the level of immunosuppression, infections, and management of other comorbidities. Risk stratification of transplant patients based on predisposing genetic modifiers and applying precision pharmacotherapy may help improving the transplant outcomes. Unlike certain fields such as oncology in which consistent attempts are being carried out to move away from the \u201cerror and trial approach,\u201d transplant medicine is lagging behind in implementing personalized immunosuppressive therapy. The need for maintaining a precarious balance between underimmunosuppression and overimmunosuppression coupled with adverse effects of medications calls for a gene-based guidance for precision pharmacotherapy in transplantation. Technologic advances in molecular genetics have led to increased accessibility of genetic tests at a reduced cost and have set the stage for widespread use of gene-based therapies in clinical care. Evidence-based guidelines available for precision pharmacotherapy have been proposed, including guidelines from Clinical Pharmacogenetics Implementation Consortium, the Pharmacogenomics Knowledge Base National Institute of General Medical Sciences of the National Institutes of Health, and the US Food and Drug Administration. In this review, we discuss the implications of pharmacogenetics and potential role for genetic variants-based risk stratification in kidney transplantation. A single score that provides overall genetic risk, a polygenic risk score, can be achieved by combining of allograft rejection\/loss-associated variants carried by an individual and integrated into practice after clinical validation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000001102","type":"journal-article","created":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T16:43:09Z","timestamp":1612629789000},"page":"e650","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Precision Medicine in Kidney Transplantation: Just Hype or a Realistic Hope?"],"prefix":"10.1097","volume":"7","author":[{"given":"Ehsan","family":"Nobakht","sequence":"first","affiliation":[{"name":"Division of Renal Diseases and Hypertension, Department of Medicine, George Washington University School of Medicine, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muralidharan","family":"Jagadeesan","sequence":"additional","affiliation":[{"name":"Division of Renal Diseases and Hypertension, Department of Medicine, George Washington University School of Medicine, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Paul","sequence":"additional","affiliation":[{"name":"Division of Renal Diseases and Hypertension, Department of Medicine, George Washington University School of Medicine, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Bromberg","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Maryland School of Medicine, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Dadgar","sequence":"additional","affiliation":[{"name":"Division of Renal Diseases and Hypertension, Department of Medicine, George Washington University School of Medicine, Washington, DC."},{"name":"Personalized Medicine Care Diagnostics Laboratory (PMCDx), Inc., Germantown, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"R1-20241001","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJM199408113310606","article-title":"Renal transplantation.","volume":"331","author":"Suthanthiran","year":"1994","journal-title":"N Engl J Med"},{"key":"R3-20241001","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jama.1993.03510110079036","article-title":"Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients.","volume":"270","author":"Port","year":"1993","journal-title":"JAMA"},{"key":"R4-20241001","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/ndt\/12.8.1672","article-title":"Patient survival after renal transplantation; more than 25 years follow-up.","volume":"12","author":"Arend","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"R5-20241001","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ajt.14557","article-title":"OPTN\/SRTR 2016 annual data report: kidney.","volume":"18","author":"Hart","year":"2018","journal-title":"Am J Transplant"},{"key":"R6-20241001","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJM200003023420901","article-title":"Improved graft survival after renal transplantation in the United States, 1988 to 1996.","volume":"342","author":"Hariharan","year":"2000","journal-title":"N Engl J Med"},{"key":"R7-20241001","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrneph.2013.18","article-title":"Transplantation: donor-specific HLA antibodies and renal allograft failure.","volume":"9","author":"Loupy","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"R8-20241001","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40262-015-0339-2","article-title":"Pharmacokinetics, pharmacodynamics and pharmacogenomics of immunosuppressants in allogeneic haematopoietic cell transplantation: part I","volume":"55","author":"McCune","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"R9-20241001","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1046\/j.1523-1755.2000.00816.x","article-title":"Long-term survival in renal transplant recipients with graft function.","volume":"57","author":"Ojo","year":"2000","journal-title":"Kidney Int"},{"key":"R10-20241001","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.2215\/CJN.04410512","article-title":"Common infections in kidney transplant recipients.","volume":"7","author":"Shamila","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R11-20241001","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra020526","article-title":"Pharmacogenomics\u2013drug disposition, drug targets, and side effects.","volume":"348","author":"Evans","year":"2003","journal-title":"N Engl J Med"},{"key":"R12-20241001","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/TP.0000000000002517","article-title":"23rd Nantes Actualit\u00e9s Transplantation: \u201cgenomics and immunogenetics of kidney and inflammatory diseases-lessons for transplantation.\u201d","volume":"103","author":"Vince","year":"2019","journal-title":"Transplantation"},{"key":"R13-20241001","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nrneph.2014.172","article-title":"Pharmacogenetics and immunosuppressive drugs in solid organ transplantation.","volume":"10","author":"van Gelder","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"R14-20241001","first-page":"82","article-title":"Cardiovascular pharmacogenomics \u2013 implications for patients with chronic kidney disease.","volume":"23","author":"Cavallari","year":"2016"},{"key":"R15-20241001","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.kint.2016.02.009","article-title":"Precision medicine comes of age in nephrology: identification of novel biomarkers and therapeutic targets for chronic kidney disease.","volume":"89","author":"Wyatt","year":"2016","journal-title":"Kidney Int"},{"key":"R16-20241001","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/tpj.2008.4","article-title":"Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions.","volume":"9","author":"Nelson","year":"2009","journal-title":"Pharmacogenomics J"},{"key":"R17-20241001","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1126\/science.286.5439.487","article-title":"Pharmacogenomics: translating functional genomics into rational therapeutics.","volume":"286","author":"Evans","year":"1999","journal-title":"Science"},{"key":"R19-20241001","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nri3820","article-title":"Immune biomarkers: the promises and pitfalls of personalized medicine.","volume":"15","author":"Willis","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"R20-20241001","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1172\/JCI78086","article-title":"Genetic basis of autoimmunity.","volume":"125","author":"Marson","year":"2015","journal-title":"J Clin Invest"},{"key":"R21-20241001","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cell.2013.08.041","article-title":"Genetic variants regulating immune cell levels in health and disease.","volume":"155","author":"Orr\u00f9","year":"2013","journal-title":"Cell"},{"key":"R22-20241001","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/TP.0b013e318186ac4a","article-title":"Impact of innate and adaptive immunity on rejection and tolerance.","volume":"86","author":"Kim","year":"2008","journal-title":"Transplantation"},{"key":"R23-20241001","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nri.2016.125","article-title":"Human immune system variation.","volume":"17","author":"Brodin","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"R24-20241001","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/TP.0000000000000878","article-title":"Epigenetics in kidney transplantation: current evidence, predictions, and future research directions","volume":"100","author":"Mas","year":"2016","journal-title":"Transplantation"},{"key":"R25-20241001","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ki.2010.335","article-title":"Beyond genetics: epigenetic code in chronic kidney disease.","volume":"79","author":"Dwivedi","year":"2011","journal-title":"Kidney Int"},{"key":"R26-20241001","doi-asserted-by":"crossref","first-page":"694","DOI":"10.4161\/epi.25201","article-title":"Epigenetic modulation of the immune function: a potential target for tolerance.","volume":"8","author":"Su\u00e1rez-\u00c1lvarez","year":"2013","journal-title":"Epigenetics"},{"key":"R27-20241001","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1097\/TP.0000000000002659","article-title":"Analysis of 75 candidate SNPs associated with acute rejection in kidney transplant recipients: validation of rs2910164 in microRNA MIR146A","volume":"103","author":"Oetting","year":"2019","journal-title":"Transplantation Direct"},{"key":"R28-20241001","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1056\/NEJM197705052961803","article-title":"Renal transplantation between HLA identical siblings. Comparison with transplants from HLA semi-identical related donors.","volume":"296","author":"Cheigh","year":"1977","journal-title":"N Engl J Med"},{"key":"R29-20241001","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1097\/TP.0000000000000836","article-title":"Using genetic variation to predict and extend long-term kidney transplant function.","volume":"99","author":"Simmonds","year":"2015","journal-title":"Transplantation"},{"key":"R30-20241001","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/ajt.14594","article-title":"Long- and short-term outcomes in renal allografts with deceased donors: a large recipient and donor genome-wide association study.","volume":"18","author":"Hernandez-Fuentes","year":"2018","journal-title":"Am J Transplant"},{"issue":"5 Pt 2","key":"R31-20241001","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/j.1600-6143.2007.01786.x","article-title":"Repeat organ transplantation in the United States, 1996\u20132005.","volume":"7","author":"Magee","year":"2007","journal-title":"Am J Transplant"},{"key":"R32-20241001","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e31827d62e3","article-title":"Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.","volume":"95","author":"Everly","year":"2013","journal-title":"Transplantation"},{"key":"R34-20241001","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1193032","article-title":"Association of trypanolytic ApoL1 variants with kidney disease in African Americans.","volume":"329","author":"Genovese","year":"2010","journal-title":"Science"},{"key":"R35-20241001","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1056\/NEJMoa1310345","article-title":"APOL1 risk variants, race, and progression of chronic kidney disease.","volume":"369","author":"Parsa","year":"2013","journal-title":"N Engl J Med"},{"key":"R36-20241001","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/j.1600-6143.2011.03513.x","article-title":"The APOL1 gene and allograft survival after kidney transplantation.","volume":"11","author":"Reeves-Daniel","year":"2011","journal-title":"Am J Transplant"},{"key":"R37-20241001","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/TP.0000000000000969","article-title":"APOL1 genotype and kidney transplantation outcomes from deceased African American donors.","volume":"100","author":"Freedman","year":"2016","journal-title":"Transplantation"},{"key":"R38-20241001","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1111\/ajt.13223","article-title":"Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure.","volume":"15","author":"Freedman","year":"2015","journal-title":"Am J Transplant"},{"key":"R39-20241001","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1193032","article-title":"Association of trypanolytic ApoL1 variants with kidney disease in African Americans.","volume":"329","author":"Giulio","year":"2010","journal-title":"Science"},{"key":"R40-20241001","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00439-010-0861-0","article-title":"Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.","volume":"128","author":"Tzur","year":"2010","journal-title":"Hum Genet"},{"key":"R41-20241001","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1000950","article-title":"Racial variation in medical outcomes among living kidney donors.","volume":"363","author":"Lentine","year":"2010","journal-title":"N Engl J Med"},{"key":"R42-20241001","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1681\/ASN.2017060658","article-title":"APOL1 genotype and renal function of black living donors.","volume":"29","author":"Doshi","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"R43-20241001","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.01510218","article-title":"The APOL1 long-term kidney transplantation outcomes network-APOLLO.","volume":"13","author":"Freedman","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"R44-20241001","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/BF02602661","article-title":"Nucleotide sequence of the human MHC class I MICA gene.","volume":"44","author":"Bahram","year":"1996","journal-title":"Immunogenetics"},{"key":"R45-20241001","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.humimm.2006.06.002","article-title":"Association of kidney transplant failure and antibodies against MICA.","volume":"67","author":"Mizutani","year":"2006","journal-title":"Hum Immunol"},{"key":"R46-20241001","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa067160","article-title":"Antibodies against MICA antigens and kidney-transplant rejection.","volume":"357","author":"Zou","year":"2007","journal-title":"N Engl J Med"},{"key":"R47-20241001","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1681\/ASN.2012080814","article-title":"MICA variant promotes allosensitization after kidney transplantation.","volume":"24","author":"Tonnerre","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"R48-20241001","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3389\/fimmu.2018.00917","article-title":"The donor major histocompatibility complex class I chain-related molecule A allele rs2596538 G predicts cytomegalovirus viremia in kidney transplant recipients.","volume":"9","author":"Rohn","year":"2018","journal-title":"Front Immunol"},{"key":"R49-20241001","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1681\/ASN.2012030260","article-title":"Donor ABCB1 variant associates with increased risk for kidney allograft failure.","volume":"23","author":"Moore","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"R50-20241001","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1111\/ajt.14894","article-title":"A donor and recipient candidate gene association study of allograft loss in renal transplant recipients receiving a tacrolimus-based regimen.","volume":"18","author":"Woillard","year":"2018","journal-title":"Am J Transplant"},{"key":"R51-20241001","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1001\/jama.2010.356","article-title":"Association of caveolin-1 gene polymorphism with kidney transplant fibrosis and allograft failure.","volume":"303","author":"Moore","year":"2010","journal-title":"JAMA"},{"key":"R52-20241001","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/TP.0b013e31825c5967","article-title":"The functional polymorphism Ala258Ser in the innate receptor gene ficolin-2 in the donor predicts improved renal transplant outcome.","volume":"94","author":"Eikmans","year":"2012","journal-title":"Transplantation"},{"key":"R53-20241001","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/ki.2013.167","article-title":"Genotypic variation and outcomes in kidney transplantation: donor and recipient effects.","volume":"84","author":"Gautreaux","year":"2013","journal-title":"Kidney Int"},{"key":"R54-20241001","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/ki.2013.195","article-title":"Low C4 gene copy numbers are associated with superior graft survival in patients transplanted with a deceased donor kidney.","volume":"84","author":"Bay","year":"2013","journal-title":"Kidney Int"},{"key":"R55-20241001","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/ajt.13912","article-title":"Genome-wide association study of acute renal graft rejection.","volume":"17","author":"Ghisdal","year":"2017","journal-title":"Am J Transplant"},{"key":"R56-20241001","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1803731","article-title":"Genomic mismatch at LIMS1 locus and kidney allograft rejection.","volume":"380","author":"Steers","year":"2019","journal-title":"N Engl J Med"},{"key":"R57-20241001","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/ajt.12298","article-title":"CMV infection in the donor and increased kidney graft loss: impact of full HLA-I mismatch and posttransplantation CD8(+) cell reduction.","volume":"13","author":"Gatault","year":"2013","journal-title":"Am J Transplant"},{"key":"R58-20241001","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.healun.2016.08.014","article-title":"Polymorphism in programmed cell death 1 gene is strongly associated with lung and kidney allograft survival in recipients from CMV-positive donors.","volume":"36","author":"Forconi","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"R59-20241001","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/tid.12285","article-title":"Interferon-gamma gene polymorphism +874 A\/T is associated with an increased risk of cytomegalovirus infection among Hispanic renal transplant recipients.","volume":"16","author":"Vu","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"R60-20241001","doi-asserted-by":"crossref","first-page":"36315","DOI":"10.1038\/srep36315","article-title":"Donor and recipient genetic variants in NLRP3 associate with early acute rejection following kidney transplantation.","volume":"6","author":"Dessing","year":"2016","journal-title":"Sci Rep"},{"key":"R61-20241001","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1681\/ASN.V133754","article-title":"Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation.","volume":"13","author":"Abdi","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R62-20241001","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1093\/ndt\/gfp317","article-title":"Genetic interactions between the donor and the recipient for susceptibility to acute rejection in kidney transplantation: polymorphisms of CCR5.","volume":"24","author":"Cha","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R63-20241001","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1016\/j.transproceed.2013.07.008","article-title":"Influence of cytotoxic T-lymphocyte antigen-4 polymorphisms on acute rejection onset of cadaveric renal transplants.","volume":"45","author":"Canossi","year":"2013","journal-title":"Transplant Proc"},{"key":"R64-20241001","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/TP.0b013e3181b2f34a","article-title":"Impact of polymorphisms of TLR4\/CD14 and TLR3 on acute rejection in kidney transplantation.","volume":"88","author":"Hwang","year":"2009","journal-title":"Transplantation"},{"key":"R65-20241001","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.transproceed.2011.06.014","article-title":"Impact of IL2 and IL2RB genetic polymorphisms in kidney transplantation.","volume":"43","author":"Park","year":"2011","journal-title":"Transplant Proc"},{"key":"R66-20241001","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00007890-200102150-00022","article-title":"Donor cytokine genotype influences the development of acute rejection after renal transplantation.","volume":"71","author":"Marshall","year":"2001","journal-title":"Transplantation"},{"key":"R67-20241001","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1097\/01.TP.0000140884.71571.BC","article-title":"Cytokine gene polymorphisms and risks of acute rejection and delayed graft function after kidney transplantation.","volume":"78","author":"Alakulppi","year":"2004","journal-title":"Transplantation"},{"key":"R68-20241001","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.1999.00536.x","article-title":"Cytokine gene polymorphisms predict acute graft rejection following renal transplantation.","volume":"56","author":"Sankaran","year":"1999","journal-title":"Kidney Int"},{"key":"R69-20241001","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1432-2277.2008.00679.x","article-title":"Association of four DNA polymorphisms with acute rejection after kidney transplantation.","volume":"21","author":"Griny\u00f3","year":"2008","journal-title":"Transpl Int"},{"key":"R70-20241001","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1097\/01.TP.0000155187.81806.DF","article-title":"The relative importance of cytokine gene polymorphisms in the development of early and late acute rejection and six-month renal allograft pathology.","volume":"79","author":"Tinckam","year":"2005","journal-title":"Transplantation"},{"key":"R71-20241001","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.trim.2013.12.002","article-title":"Association between IVS3\u2009+\u200917T\/C CD28 gene polymorphism and the acute kidney allograft rejection.","volume":"30","author":"Pawlik","year":"2014","journal-title":"Transpl Immunol"},{"key":"R72-20241001","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.kint.2015.11.025","article-title":"Polymorphisms in the lectin pathway of complement activation influence the incidence of acute rejection and graft outcome after kidney transplantation.","volume":"89","author":"Golshayan","year":"2016","journal-title":"Kidney Int"},{"key":"R73-20241001","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1111\/ajt.14199","article-title":"Complement polymorphisms in kidney transplantation: critical in graft rejection?","volume":"17","author":"Michielsen","year":"2017","journal-title":"Am J Transplant"},{"key":"R74-20241001","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/01.ASN.0000039567.22063.9D","article-title":"Outcome of kidney transplantation in patients with inherited thrombophilia: data of a prospective study.","volume":"14","author":"Heidenreich","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R75-20241001","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13073-020-00742-5","article-title":"Polygenic risk scores: from research tools to clinical instruments.","volume":"12","author":"Lewis","year":"2020","journal-title":"Genome Med"},{"key":"R76-20241001","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1126\/science.161.3836.72","article-title":"Genetic control of drug levels in man: antipyrine.","volume":"161","author":"Vesell","year":"1968","journal-title":"Science"},{"key":"R77-20241001","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1126\/science.159.3822.1479","article-title":"Genetic control of drug levels in man: phenylbutazone.","volume":"159","author":"Vesell","year":"1968","journal-title":"Science"},{"key":"R78-20241001","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1749-6632.1971.tb46950.x","article-title":"Genetic control of drug levels and of the induction of drug-metabolizing enzymes in man: individual variability in the extent of allopurinol and nortriptyline inhibition of drug metabolism.","volume":"179","author":"Vesell","year":"1971","journal-title":"Ann N Y Acad Sci"},{"key":"R79-20241001","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature15817","article-title":"Pharmacogenomics in the clinic.","volume":"526","author":"Relling","year":"2015","journal-title":"Nature"},{"key":"R80-20241001","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(19)31276-0","article-title":"Pharmacogenomics.","volume":"394","author":"Roden","year":"2019","journal-title":"Lancet"},{"key":"R81-20241001","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12014-016-9127-8","article-title":"Precision medicine: from pharmacogenomics to pharmacoproteomics.","volume":"13","author":"Chambliss","year":"2016","journal-title":"Clin Proteomics"},{"key":"R82-20241001","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2215\/CJN.02730218","article-title":"Clinical pharmacogenomics: applications in nephrology.","volume":"13","author":"Adams","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"R83-20241001","first-page":"652","article-title":"Spectrum of Lactobacillus species present in healthy vagina of Indian women.","volume":"129","author":"Garg","year":"2009","journal-title":"Indian J Med Res"},{"key":"R84-20241001","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2215\/CJN.03800415","article-title":"Induction therapy in renal transplantation: why? What agent? What dose? We may never know.","volume":"10","author":"Wiseman","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 3","key":"R85-20241001","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients.","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"R86-20241001","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation.","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R87-20241001","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1080\/10428190802163321","article-title":"Mechanisms of action of antithymocyte globulin: old dogs with new tricks!","volume":"49","author":"Mohty","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"R88-20241001","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1681\/ASN.2006050422","article-title":"A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells.","volume":"17","author":"Lopez","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R89-20241001","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/eji.200737821","article-title":"Interleukin-10 regulates TNF-alpha-converting enzyme (TACE\/ADAM-17) involving a TIMP-3 dependent and independent mechanism.","volume":"38","author":"Brennan","year":"2008","journal-title":"Eur J Immunol"},{"key":"R90-20241001","first-page":"17060","article-title":"Association between tumor necrosis factor-alpha (TNF-alpha) polymorphism (-308, G\/A) and acute rejection of solid organ allograft: a meta-analysis.","volume":"9","author":"Park","year":"2016","journal-title":"Int J Clin Exp Med"},{"key":"R91-20241001","doi-asserted-by":"crossref","first-page":"2197595","DOI":"10.1155\/2016\/2197595","article-title":"The polymorphism -308G\/A of tumor necrosis factor-\u03b1 gene modulates the effect of immunosuppressive treatment in first kidney transplant subjects who suffer an acute rejection.","volume":"2016","author":"S\u00e1nchez-Fructuoso","year":"2016","journal-title":"J Immunol Res"},{"issue":"Suppl 2","key":"R92-20241001","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action of rituximab.","volume":"13","author":"Cerny","year":"2002","journal-title":"Anticancer Drugs"},{"key":"R93-20241001","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/01.TP.0000078622.43689.D4","article-title":"Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab.","volume":"76","author":"Tyd\u00e9n","year":"2003","journal-title":"Transplantation"},{"key":"R94-20241001","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/ame2.12064","article-title":"Rituximab in kidney disease and transplant.","volume":"2","author":"Chauhan","year":"2019","journal-title":"Animal Model Exp Med"},{"key":"R95-20241001","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1097\/TXD.0000000000000683","article-title":"Effect of Fc-\u03b3 receptor polymorphism on rituximab-mediated B cell depletion in ABO-incompatible adult living donor liver transplantation.","volume":"3","author":"Sakai","year":"2017","journal-title":"Transplant Direct"},{"key":"R96-20241001","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"R97-20241001","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/0952-7915(94)90120-1","article-title":"CD28-B7 interactions in T-cell activation.","volume":"6","author":"Allison","year":"1994","journal-title":"Curr Opin Immunol"},{"key":"R98-20241001","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"CTLA-4 can function as a negative regulator of T cell activation.","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity"},{"key":"R99-20241001","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1600-6143.2005.00749.x","article-title":"Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.","volume":"5","author":"Larsen","year":"2005","journal-title":"Am J Transplant"},{"key":"R100-20241001","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Eng J Med"},{"key":"R101-20241001","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1111\/ajt.14350","article-title":"Increased pretransplant frequency of CD28+ CD4+ TEM predicts belatacept-resistant rejection in human renal transplant recipients.","volume":"17","author":"Cortes-Cerisuelo","year":"2017","journal-title":"Am J Transplant"},{"issue":"3 Suppl","key":"R102-20241001","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1097\/TP.0b013e3181afe9e7","article-title":"Pharmacogenetics of calcineurin inhibitors in renal transplantation.","volume":"88","author":"Coto","year":"2009","journal-title":"Transplantation"},{"key":"R103-20241001","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/FTD.0000000000000542","article-title":"Impact of POR and CYP3A5 polymorphisms on trough concentration to dose ratio of tacrolimus in the early post-operative period following kidney transplantation.","volume":"40","author":"Phupradit","year":"2018","journal-title":"Ther Drug Monit"},{"key":"R104-20241001","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00228-018-2521-6","article-title":"Evaluating tacrolimus pharmacokinetic models in adult renal transplant recipients with different CYP3A5 genotypes.","volume":"74","author":"Hu","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"R105-20241001","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/TP.0b013e318200e991","article-title":"Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium.","volume":"91","author":"Jacobson","year":"2011","journal-title":"Transplantation"},{"key":"R106-20241001","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1111\/j.1600-6143.2006.01518.x","article-title":"CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study.","volume":"6","author":"Haufroid","year":"2006","journal-title":"Am J Transplant"},{"key":"R107-20241001","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1097\/01.TP.0000137789.58694.B4","article-title":"Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.","volume":"78","author":"Tsuchiya","year":"2004","journal-title":"Transplantation"},{"key":"R108-20241001","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1472-8206.2007.00504.x","article-title":"Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.","volume":"21","author":"Op den Buijsch","year":"2007","journal-title":"Fundam Clin Pharmacol"},{"key":"R109-20241001","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","article-title":"Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.","volume":"74","author":"Hesselink","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R110-20241001","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00008571-200403000-00002","article-title":"The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.","volume":"14","author":"Haufroid","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R111-20241001","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/ctr.12376","article-title":"Tacrolimus dose requirements in African-American and Caucasian kidney transplant recipients on mycophenolate and prednisone.","volume":"28","author":"Beermann","year":"2014","journal-title":"Clin Transplant"},{"key":"R112-20241001","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1111\/ajt.15385","article-title":"Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: a comparison of four ancestry groups.","volume":"19","author":"Mohamed","year":"2019","journal-title":"Am J Transplant"},{"key":"R113-20241001","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/FPC.0b013e3283557c74","article-title":"The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis.","volume":"22","author":"Terrazzino","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"R114-20241001","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing.","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"R115-20241001","first-page":"721","article-title":"Optimization of initial tacrolimus dose using pharmacogenetic testing.","volume":"87","author":"Thervet","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R116-20241001","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/ajt.13691","article-title":"A randomized controlled trial comparing the efficacy of Cyp3a5 genotype-based with body-weight-based tacrolimus dosing after living donor kidney transplantation.","volume":"16","author":"Shuker","year":"2016","journal-title":"Am J Transplant"},{"key":"R117-20241001","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2217\/pgs-2017-0131","article-title":"Genotype-based tacrolimus dosing guidelines: with or without CYP3A4*22?","volume":"18","author":"Elens","year":"2017","journal-title":"Pharmacogenomics"},{"key":"R118-20241001","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.clpt.6100216","article-title":"CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.","volume":"82","author":"Kuypers","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R119-20241001","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/FTD.0b013e31829da6dd","article-title":"Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients.","volume":"36","author":"Elens","year":"2014","journal-title":"Ther Drug Monit"},{"key":"R120-20241001","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/00008571-200410000-00004","article-title":"The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients.","volume":"14","author":"Kreutz","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R121-20241001","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/FPC.0b013e3282f3ef72","article-title":"Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms.","volume":"18","author":"Fanta","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R122-20241001","doi-asserted-by":"crossref","first-page":"12360","DOI":"10.1021\/acs.analchem.7b03404","article-title":"Validating quantitative untargeted lipidomics across nine liquid chromatography-high-resolution mass spectrometry platforms.","volume":"89","author":"Cajka","year":"2017","journal-title":"Anal Chem"},{"key":"R123-20241001","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1360-0443.2006.01648.x","article-title":"The effect of assertive continuing care on continuing care linkage, adherence and abstinence following residential treatment for adolescents with substance use disorders.","volume":"102","author":"Godley","year":"2007","journal-title":"Addiction"},{"key":"R124-20241001","doi-asserted-by":"crossref","first-page":"716","DOI":"10.7326\/0003-4819-129-9-199811010-00007","article-title":"Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine.","volume":"129","author":"Black","year":"1998","journal-title":"Ann Intern Med"},{"key":"R125-20241001","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nature24628","article-title":"Salt-responsive gut commensal modulates TH17 axis and disease.","volume":"551","author":"Wilck","year":"2017","journal-title":"Nature"},{"key":"R126-20241001","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/01.fpc.0000114745.08559.db","article-title":"Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants.","volume":"14","author":"Schaeffeler","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R127-20241001","doi-asserted-by":"crossref","first-page":"608","DOI":"10.7326\/0003-4819-126-8-199704150-00003","article-title":"Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance.","volume":"126","author":"Yates","year":"1997","journal-title":"Ann Intern Med"},{"key":"R128-20241001","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update.","volume":"105","author":"Relling","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"R129-20241001","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/11599710-000000000-00000","article-title":"Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients.","volume":"51","author":"Moes","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"R130-20241001","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/mmy\/myv099","article-title":"Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels.","volume":"54","author":"Guinea","year":"2016","journal-title":"Med Mycol"},{"key":"R131-20241001","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/cpt.953","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy.","volume":"103","author":"Moriyama","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"R132-20241001","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jcin.2017.07.022","article-title":"Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention.","volume":"11","author":"Cavallari","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"R133-20241001","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIR.0b013e318256f1e0","article-title":"2012 ACCF\/AHA focused update of the guideline for the management of patients with unstable angina\/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines.","volume":"126","author":"Jneid","year":"2012","journal-title":"Circulation"},{"key":"R134-20241001","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.","volume":"94","author":"Scott","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"R135-20241001","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/cpt.668","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update.","volume":"102","author":"Johnson","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R136-20241001","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/clpt.2013.254","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.","volume":"95","author":"Crews","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"R137-20241001","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80\u2009mg versus 20\u2009mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial.","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"R138-20241001","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study.","volume":"359","author":"Link","year":"2008","journal-title":"N Eng J Med"},{"key":"R139-20241001","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.","volume":"102","author":"Shuen-lu","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R140-20241001","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/clpt.2012.209","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.","volume":"93","author":"Hershfield","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"R142-20241001","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40472-015-0052-y","article-title":"The cost of transplant immunosuppressant therapy: is this sustainable?","volume":"2","author":"James","year":"2015","journal-title":"Curr Transplant Rep"},{"key":"R143-20241001","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.","volume":"279","author":"Lazarou","year":"1998","journal-title":"JAMA"},{"key":"R144-20241001","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1001\/archinte.1995.00430180043006","article-title":"Drug-related morbidity and mortality. A cost-of-illness model.","volume":"155","author":"Johnson","year":"1995","journal-title":"Arch Intern Med"},{"key":"R145-20241001","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/phar.1145","article-title":"Medication errors and adverse drug events in kidney transplant recipients: incidence, risk factors, and clinical outcomes.","volume":"32","author":"Taber","year":"2012","journal-title":"Pharmacotherapy"},{"key":"R146-20241001","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2174\/157488631102160429003742","article-title":"A systematic approach to assess the burden of drug interactions in adult kidney transplant patients.","volume":"11","author":"Fernando","year":"2016","journal-title":"Current Drug Safety"},{"key":"R147-20241001","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMsb1503104","article-title":"Precision medicine\u2013personalized, problematic, and promising.","volume":"372","author":"Jameson","year":"2015","journal-title":"N Engl J Med"},{"key":"R148-20241001","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature08821","article-title":"A human gut microbial gene catalogue established by metagenomic sequencing.","volume":"464","author":"Qin","year":"2010","journal-title":"Nature"},{"key":"R149-20241001","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41397-019-0123-z","article-title":"Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view.","volume":"20","author":"Varnai","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"R150-20241001","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3389\/fgene.2019.01084","article-title":"Genome-wide study updates in the international genetics and translational research in transplantation network (iGeneTRAiN).","volume":"10","author":"Fishman","year":"2019","journal-title":"Front Genet"},{"key":"R151-20241001","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nrg.2016.27","article-title":"Developing and evaluating polygenic risk prediction models for stratified disease prevention.","volume":"17","author":"Chatterjee","year":"2016","journal-title":"Nat Rev Genet"},{"key":"R152-20241001","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41576-018-0018-x","article-title":"The personal and clinical utility of polygenic risk scores.","volume":"19","author":"Torkamani","year":"2018","journal-title":"Nat Rev Genet"},{"key":"R153-20241001","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cmet.2018.12.009","article-title":"Moving beyond GWAS and eQTL analysis to validated hits in chronic kidney disease.","volume":"29","author":"M\u00fcller-Deile","year":"2019","journal-title":"Cell Metab"},{"key":"R154-20241001","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMc1903250","article-title":"Diagnostic utility of exome sequencing for kidney disease.","volume":"380","author":"Carriazo","year":"2019","journal-title":"N Engl J Med"},{"key":"R155-20241001","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(05)79055-3","article-title":"Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients.","volume":"351","author":"Lo","year":"1998","journal-title":"Lancet"},{"key":"R156-20241001","doi-asserted-by":"crossref","first-page":"6229","DOI":"10.1073\/pnas.1013924108","article-title":"Universal noninvasive detection of solid organ transplant rejection.","volume":"108","author":"Snyder","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R157-20241001","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.jmoldx.2016.07.003","article-title":"Validation of a clinical-grade assay to measure donor-derived cell-free DNA in solid organ transplant recipients.","volume":"18","author":"Grskovic","year":"2016","journal-title":"J Mol Diagn"},{"key":"R158-20241001","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1681\/ASN.2016091034","article-title":"Cell-free DNA and active rejection in kidney allografts.","volume":"28","author":"Bloom","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R159-20241001","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/j.ajkd.2015.09.027","article-title":"Role of the gut microbiome in uremia: a potential therapeutic target.","volume":"67","author":"Ramezani","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"R160-20241001","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s13238-010-0093-z","article-title":"Human gut microbiome: the second genome of human body.","volume":"1","author":"Zhu","year":"2010","journal-title":"Protein Cell"},{"key":"R161-20241001","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd2505","article-title":"Gut microbiota: a potential new territory for drug targeting.","volume":"7","author":"Jia","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"R162-20241001","article-title":"Metabolic synergy to uremic toxicity: a tale of symbiosis and dysbiosis in CKD.","volume":"18","author":"Paul","year":"2019","journal-title":"Nephrol Self-Assessment"},{"key":"R163-20241001","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/cpt.1437","article-title":"Pharmacomicrobiomics: the holy grail to variability in drug response?","volume":"106","author":"Sharma","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"R164-20241001","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nrgastro.2017.20","article-title":"Gut microbiota modulation of chemotherapy efficacy and toxicity.","volume":"14","author":"Alexander","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R165-20241001","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/01.tp.0000206102.67063.24","article-title":"Relationship between subclinical rejection and genotype, renal messenger RNA, and plasma protein transforming growth factor-beta1 levels.","volume":"81","author":"Hueso","year":"2006","journal-title":"Transplantation"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T18:01:25Z","timestamp":1727805685000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":161,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001102","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]}}}